- Home
- IGI vs CLLS Comparison
IGI vs CLLS Comparison
Compare IGI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGI
- CLLS
- Stock Information
- Founded
- IGI 2009
- CLLS 1999
- Country
- IGI United States
- CLLS France
- Employees
- IGI N/A
- CLLS N/A
- Industry
- IGI Investment Managers
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- IGI Finance
- CLLS Health Care
- Exchange
- IGI Nasdaq
- CLLS Nasdaq
- Market Cap
- IGI 174.9M
- CLLS 148.1M
- IPO Year
- IGI N/A
- CLLS 2007
- Fundamental
- Price
- IGI $16.12
- CLLS $1.45
- Analyst Decision
- IGI
- CLLS Buy
- Analyst Count
- IGI 0
- CLLS 3
- Target Price
- IGI N/A
- CLLS $7.00
- AVG Volume (30 Days)
- IGI 33.9K
- CLLS 120.5K
- Earning Date
- IGI 01-01-0001
- CLLS 05-27-2025
- Dividend Yield
- IGI 4.79%
- CLLS N/A
- EPS Growth
- IGI N/A
- CLLS N/A
- EPS
- IGI N/A
- CLLS N/A
- Revenue
- IGI N/A
- CLLS $49,217,000.00
- Revenue This Year
- IGI N/A
- CLLS $1.26
- Revenue Next Year
- IGI N/A
- CLLS N/A
- P/E Ratio
- IGI N/A
- CLLS N/A
- Revenue Growth
- IGI N/A
- CLLS 435.38
- 52 Week Low
- IGI $15.13
- CLLS $1.10
- 52 Week High
- IGI $17.79
- CLLS $3.38
- Technical
- Relative Strength Index (RSI)
- IGI 40.08
- CLLS 60.38
- Support Level
- IGI $15.76
- CLLS $1.40
- Resistance Level
- IGI $16.22
- CLLS $1.56
- Average True Range (ATR)
- IGI 0.31
- CLLS 0.09
- MACD
- IGI -0.02
- CLLS 0.03
- Stochastic Oscillator
- IGI 40.00
- CLLS 76.09
About IGI Western Asset Investment Grade Defined Opportunity Trust Inc.
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.